里氏转化 (RT) 被定义为 2-10% 的慢性淋巴细胞白血病 (CLL) 患者发展为侵袭性淋巴瘤。到目前为止，波兰尚未对 RT 人口统计和治疗结果进行复杂的分析。因此，设计了对来自波兰血液中心的 124 名 RT 患者的回顾性分析。确定了 99 名弥漫性大 B 细胞淋巴瘤 (DLBCL-RT) 患者。 DLBCL-RT 的中位总生存期 (OS) 为 17.3 个月，而霍奇金淋巴瘤 (HL-RT) 的中位总生存期 (OS) 为 -21.3 个月。在多变量分析中，DLBCL-RT 的 OS 较差的独立因素是：既往 CLL 治疗、ECOG 分期≥2 期和血清 LDH 活性升高。接受造血干细胞移植（HSCT）的患者取得了更好的结果。同种异体 HSCT 受者的中位 OS 尚未达到，而自体 HSCT 受者的中位 OS 为 51.3 个月。总之，我们的研究代表了波兰诊断为 RT 的患者的最大数据集，并证实了其令人沮丧的预后。

Richter transformation (RT) is defined as developing an aggressive lymphoma in 2-10% of patients suffering from chronic lymphocytic leukemia (CLL). So far, no complex analysis of RT demographics and treatment outcomes has been performed in Poland. Thus, the retrospective analysis of 124 patients with RT from Polish hematology centers was designed. Ninety-nine patients with diffuse large B-cell lymphoma (DLBCL-RT) were identified. The median overall survival (OS) for DLBCL-RT was 17.3 months, while for Hodgkin lymphoma (HL-RT)-21.3 months. In multivariate analysis, the independent factors of worse OS for DLBCL-RT were: prior CLL therapy, ECOG stage ≥2, and elevated serum LDH activity. Patients who proceeded to hematopoietic stem cell transplantation (HSCT) achieved better results. The median OS in allogeneic HSCT recipients was not reached, while in autologous HSCT median OS was 51.3 months. In conclusion, our study represents the largest dataset of patients diagnosed with RT in Poland and confirms its dismal prognosis.